Literature DB >> 10820984

Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study).

R P Croft1, P G Nicholls, J H Richardus, W C Smith.   

Abstract

In this paper, the incidence rates and cumulative incidence of nerve function impairment (NFI) and leprosy reactions over 24 months follow-up of the prospective cohort of 2664 new leprosy cases are presented. Graphs showing the cumulative incidence of NFI relative to time since registration are presented. Hazard ratios (HRs) for the development of NFI for four variables are given. The majority of patients who developed NFI after registration did so in the first year (67% of multibacillary (MB) patients, and 91% of paucibacillary (PB) patients who developed NFI). Thirty-three percent of all MB patients who developed NFI after registration did so in the second year of follow-up. No PB patients developed NFI for the first time in the last 6 months of follow-up. However, seven NFI events occurred amongst PB patients in that period, amongst those who had already had one NFI event. The incidence rate (IR) of NFI amongst MB patients was 24/100 person-years at risk (PYAR), and amongst PB patients was 1.3/100 PYAR. The HR for the development of NFI amongst MB patients compared with PB patients was 16 using univariate analysis. Amongst patients who had long-standing NFI present at registration, the IR was 27/100 PYAR compared with 1.7/100 PYAR amongst those who did not have long-standing NFI. The HR for developing acute NFI amongst those with long-standing NFI present at registration compared with those without was 14 using univariate analysis. When multivariate regression analysis is applied, the apparently significant univariate HRs for sex and age disappeared. The resultant multivariate HR for leprosy group is 8.8, and 6.1 for the presence/absence of long-standing NFI at registration. In all, 142/166 (86%) of all new NFI events were silent, underlining the need for regular nerve function testing. IRs are presented for the four 6-month periods of the 24-month follow-up. They show a clear stepwise reduction over the total period. The IRs amongst MB patients and those with long-standing NFI present at registration are very high at 34 and 41/100 PYAR, respectively, for the first 6 months of follow-up. Even during the final 6-month period, the IR is maintained at a moderately high level (18 and 15/100 PYAR, respectively).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820984     DOI: 10.5935/0305-7518.20000004

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

1.  Evidence for Mycobacterium leprae Drug Resistance in a Large Cohort of Leprous Neuropathy Patients from India.

Authors:  Niranjan Prakash Mahajan; Mallika Lavania; Itu Singh; Saraswati Nashi; Veeramani Preethish-Kumar; Seena Vengalil; Kiran Polavarapu; Chevula Pradeep-Chandra-Reddy; Muddasu Keerthipriya; Anita Mahadevan; Tagaduru Chickabasaviah Yasha; Bevinahalli Nanjegowda Nandeesh; Krishnamurthy Gnanakumar; Gareth J Parry; Utpal Sengupta; Atchayaram Nalini
Journal:  Am J Trop Med Hyg       Date:  2020-03       Impact factor: 2.345

2.  Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).

Authors:  W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus
Journal:  BMJ       Date:  2004-05-24

Review 3.  Treatment and Evaluation Advances in Leprosy Neuropathy.

Authors:  Gigi J Ebenezer; David M Scollard
Journal:  Neurotherapeutics       Date:  2021-11-19       Impact factor: 7.620

Review 4.  Systematic Review of Survival Analysis in Leprosy Studies-Including the Following Outcomes: Relapse, Impairment of Nerve Function, Reactions and Physical Disability.

Authors:  Celivane Cavalcanti Barbosa; Gilberto Silva Nunes Bezerra; Amanda Tavares Xavier; Maria de Fátima Pessoa Militão de Albuquerque; Cristine Vieira do Bonfim; Zulma Maria de Medeiros; Wayner Vieira de Souza
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

5.  Early diagnosis of neuropathy in leprosy--comparing diagnostic tests in a large prospective study (the INFIR cohort study).

Authors:  Wim H van Brakel; Peter G Nicholls; Einar P Wilder-Smith; Loretta Das; Pramila Barkataki; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2008-04-02

6.  Progression of leprosy disability after discharge: is multidrug therapy enough?

Authors:  Anna Maria Sales; Dayse Pereira Campos; Mariana Andrea Hacker; José Augusto da Costa Nery; Nádia Cristina Düppre; Emanuel Rangel; Euzenir Nunes Sarno; Maria Lucia Fernandes Penna
Journal:  Trop Med Int Health       Date:  2013-09       Impact factor: 2.622

7.  Early detection of neuropathy in leprosy: a comparison of five tests for field settings.

Authors:  Inge Wagenaar; Erik Post; Wim Brandsma; Dan Ziegler; Moshiur Rahman; Khorshed Alam; Jan Hendrik Richardus
Journal:  Infect Dis Poverty       Date:  2017-09-01       Impact factor: 4.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.